Last updated: August 16, 2026

Application No. 18/273,297

COMPOSITION FOR SUPPRESSING DETERIORATION OF OR ENHANCING MEMORY LEARNING FUNCTION AND/OR COGNITIVE FUNCTION

Final Rejection

Filed

Jul 20, 2023

Priority

Jan 25, 2021 — JP 2021-009348 +1 more

Examiner

DEVI, SARVAMANGALA

Art Unit

1645

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

DIC Corporation

OA Round

2 (Final)

Interview Optional

— +55.0% interview lift. Examiner has a relatively high allowance rate (65%); +55.0% interview lift. A written response may suffice.

Based on 871 resolved cases, 2023–2026

Examiner Intelligence

DEVI, SARVAMANGALA View full profile →

Grants 65% — above average

Career Allowance Rate

569 granted / 871 resolved

+5.3% vs TC avg

Strong +55% interview lift

Without

With

+55.0%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

48 currently pending

Career history

927

Total Applications

across all art units

Statute-Specific Performance

§101

7.1%

-32.9% vs TC avg

§103

17.7%

-22.3% vs TC avg

§102

25.6%

-14.4% vs TC avg

§112

43.5%

+3.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 871 resolved cases

Prosecution Timeline

Jul 20, 2023

Application Filed

Feb 11, 2026

Non-Final Rejection mailed

May 11, 2026

Response Filed

Aug 05, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/261,975

Patent 12697379

PEGYLATED TETANUS NEUROTOXINS AND TREATMENT OF HYPOTONIA

5y 6m to grant Granted Aug 04, 2026

17/602,628

Patent 12699090

DIAGNOSTIC REAGENTS

4y 10m to grant Granted Aug 04, 2026

18/530,348

Patent 12691167

PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING KLEBSIELLA PROTEINS AND METHODS OF USE

2y 7m to grant Granted Jul 28, 2026

17/757,972

Patent 12667611

NEW USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A RESPIRATORY SYNCITIAL VIRUS PROTEIN AGAINST hMPV

4y 0m to grant Granted Jun 30, 2026

18/425,772

Patent 12661411

MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGE

2y 4m to grant Granted Jun 23, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

65%

Grant Probability

99%

With Interview (+55.0%)

3y 4m (~3m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 871 resolved cases by this examiner. Grant probability derived from career allowance rate.